Levine Leichtman Capital Partners Portfolio Company Trinity Consultants Acquires AWN Consulting

Levine Leichtman

LOS ANGELES, CA , January 6, 2021
Trinity Consultants, Inc. (“Trinity”), a portfolio company of Levine Leichtman Capital Partners (“LLCP”), announced that it has acquired AWN Consulting International Limited (“AWN Consulting”). AWN Consulting, based in Dublin, Ireland, provides environmental, acoustics, and risk management consulting services to industrial and public sector clients throughout Ireland and Europe.

Trinity is a leading provider of regulatory-driven environmental, health & safety and engineering consulting services. Trinity specializes in highly technical, compliance-driven services with a core presence in air quality and an expanding presence in adjacencies such as commissioning, qualification and validation, process safety management, toxicology, acoustics and water quality. Trinity operates from over 70 offices worldwide, with a national U.S. footprint and a presence in key international markets. Trinity was founded in 1974 and is headquartered in Dallas, Texas.

Jay Hofmann, President and CEO of Trinity, commented, “We are pleased to bring AWN Consulting onto the Trinity platform. The acquisition further bolsters Trinity’s core capabilities and strategically expands our geographic presence into Ireland.”

Andrew Schwartz, a Partner at LLCP, stated, “We are excited to demonstrate our continued support of Trinity through this acquisition. AWN Consulting strengthens Trinity’s ability to provide regulatory and compliance support to its clients across the globe.”

Trinity is a portfolio company of Levine Leichtman Capital Partners Fund V, L.P.

About Levine Leichtman Capital Partners

Levine Leichtman Capital Partners, LLC is a middle-market private equity firm with a 37-year track record of investing across various targeted sectors, including franchising, professional services, education and engineered products. LLCP utilizes a differentiated Structured Private Equity investment strategy, combining debt and equity capital investments in portfolio companies. This unique structure provides a less dilutive solution for management teams and entrepreneurs, while delivering growth and income with a significantly lower risk profile.

LLCP’s global team of dedicated investment professionals is led by seven partners who have worked at LLCP for an average of 21 years. Since inception, LLCP has managed approximately $11.2 billion of institutional capital across 14 investment funds and has invested in over 90 portfolio companies. LLCP currently manages approximately $7.3 billion of assets – including its most recent flagship fund, Levine Leichtman Capital Partners VI, L.P., which closed in 2018 with $2.5 billion of committed capital – and has offices in Los Angeles, New York, Chicago, Charlotte, Miami, London, Stockholm and The Hague.

Categories: News

Tags:

Vendis Capital teams up with founders & management to accelerate the development of Dutch retailer Vendis Capital teams up with founders & management to accelerate the development of Dutch retailer SoLow

Vendis Capital

Utrecht (NL), 5 January 2021 – Vendis Capital, the consumer sector specialized European private equity fund, invests in SoLow, a Dutch retailer with a fun offering of party, hobby & craft and other non-food articles with affordable pricing.

SoLow, headquartered in Culemborg (The Netherlands), is a uniquely differentiated retailer with a deep assortment in party, hobby & craft as well as a broad offering in other fun non-food articles, all available at affordable prices. The company was founded in 2003 by the brothers Danny and Francois Dame, who started selling these products from a stall on local street markets. Building on their success, they started opening permanent stores under the SoLow brand. Since then they have delivered considerable growth in both absolute and like-for-like sales. The company currently operates 35 SoLow stores throughout the Netherlands.

Vendis Capital teams up with the two brothers to further accelerate the growth and development of the company. To do so a new management team comprising a mix of current and new employees is formed. This team will be led by Gert-Jan Becks (CEO). Gert-Jan brings significant experience from his past roles at amongst others Swinkels Family Brewers, Bacardi-Martini and Nestlé.

Danny Dame, co-founder, and current CEO of SoLow, is proud of the successes he and his team have made in building the SoLow format. He believes that Vendis Capital is the right partner for SoLow to continue this success: “The qualities of Vendis Capital, amongst others their successful track-record within the retail industry and experience with optimizing and rolling-out retail formats, will add to Solow’s further development”

David de Graaf, Investment Director at Vendis Capital: “SoLow fits Vendis’ investment criteria very well; it presents a retailer in the large and growing non-food discount segment with a differentiated format that is well positioned for further growth. We are excited about partnering with SoLow and look forward to bring its unique offering to more and more customers.”

The participation in SoLow represents the second investment within Vendis Capital III, the €300 million fund that was launched in 2019.

Categories: News

Tags:

Thoma Bravo announces Senior Appointments

Thomas Bravo

Gerald “Jerry” Nowak Joins as General Counsel and Chief Administrative Officer

Jennifer James Promoted to Chief Operating Officer

SAN FRANCISCOThoma Bravo, a leading private equity investment firm focused on the software and technology-enabled services sector, today announced appointments within its senior leadership team in operations.

Gerald “Jerry” Nowak joins Thoma Bravo as a Managing Director and General Counsel, Chief Administrative Officer. Previously, Nowak served as a Partner in the Chicago office of Kirkland & Ellis LLP, where he was a leader in the firm’s Private Equity, M&A and Capital Markets practices, working closely with Thoma Bravo for almost 20 years on a variety of transactions and mandates. In this new role, Nowak will lead Thoma Bravo’s Legal & Compliance, IT and other Administrative functions.

Jennifer James will assume an expanded role as Chief Operating Officer, in addition to her role as Managing Director, Head of Investor Relations and Marketing. During her five-year tenure at Thoma Bravo, James has fostered deep relationships with investors on the firm’s behalf and was instrumental in executing the firm’s recent $22.8 billion fundraise. Thoma Bravo’s Investor Relations, Marketing & Communications, Human Resources and other Operational functions will report to James, who will work closely with Nowak to continue building a best-in-class operations team.

“This was a successful year for Thoma Bravo as we closed our biggest fundraise to date and continued to see growth across our portfolio of leading software and technology companies,” said Orlando Bravo, a founder and Managing Partner at Thoma Bravo. “We begin 2021 in a prime position to take advantage of the many opportunities in the market, supported by a phenomenal team which we are excited to continue to grow. Over the years, Jerry has been a tremendous partner to Thoma Bravo, and I am thrilled to welcome him to our team and continue to work together. His appointment, in addition to Jennifer’s expanded role as COO, reflects the deep bench of talent we have developed. I couldn’t be more excited to work with our growing leadership team as we position the firm for the long-term.”

About Thoma Bravo
Thoma Bravo is a leading private equity firm focused on the software and technology-enabled services sectors. With more than $73 billion in assets under management as of September 30, 2020, Thoma Bravo partners with a company’s management team to implement operating best practices, invest in growth initiatives and make accretive acquisitions intended to accelerate revenue and earnings, with the goal of increasing the value of the business. The firm has offices in San Francisco and Chicago. For more information, visit thomabravo.com.

Read the release on the PR Newswire website here.

Categories: People

Fight against climat change: Fermentalg and SUEZ create a joint venture to accelerate the industrialization and commercialization of solutions for capturing and valorizing CO2 in bioproducts

Suez Ventures

Strengthened by their feedback following a five-year partnership, and to address the growing climate emergency, SUEZ and FERMENTALG, a key French player and expert in the research and bio industrial exploitation of micro-algae, have signed a memorandum of understanding for the creation in the first half of 2021 of a joint venture, equally owned, which will develop algae photobioreactors capable of capturing CO2 by biomimicry. In addition, this major innovation will enable the development of circular loops, notably by producing products that can be used in the fields of biocontrol, nutrition and animal health.

Initiated in 2015 as part of the Paris Agreement, the partnership between FERMENTALG and SUEZ has allowed for the development of unique and promising solutions in response to the environmental challenges of the 21st century:

  • Carbon sink, to capture and process CO2 emissions in an industrial environment using a new generation algae photobioreactor;
  • The Combin’Air air purifier, including innovative solutions such as an algae photobioreactor designed to reduce fine particles (PM10, PM2.5) and nitrogen dioxide (NOx) to combat the toxic impacts of atmospheric pollution on public health.

The new algal photobioreactor developed by the joint venture will build on these first technological advances deployed in both industrial and urban environments over the past five years. The solutions improve the selection of microalgae strains, new lighting technologies and the identification of high value-added bioproducts validating the environmental and economic benefits of the model. According to the applications, these bioproducts will contribute to the preservation of soils and biodiversity as well as to human and animal health.

Philippe Lavielle, FERMENTALG CEO, commented: “By creating this new growth division with SUEZ Group, FERMENTALG today reaffirms its environmental and societal commitment. By leveraging our unique global expertise in technology to serve sustainable development, our joint venture will now be positioned as one of the leading players in air quality and the fight against climate change. In the first year, we plan to open up our capital to other financial partners to accelerate the global rollout of our solutions.”

Diane Galbe, Senior Executive Vice President Group in charge of the global Business Unit, Smart & Environmental Solutions and Head of Strategy, added: “This joint venture with Fermentalg is fully in line with our Group’s strategy by providing solutions for the capture and recovery of CO2 in bioproducts. This new nature-based solutions will have a positive impact on climate, health and biodiversity while fully meeting the challenges of the circular economy. Five years after the Paris agreement aimed at containing global warming to 1.5° by the end of the century, SUEZ is once again translating its reinforced commitments to preserve our planet into concrete solutions to build a sustainable world, starting now.

  • 299KB
  • PDF
  • pdf

Download the press release

Download the press release

Categories: News

Tags:

Clearlake to make Strategic Investment in Web.com

Siris

Web Presence Market Leader Poised for Accelerated Growth

Santa Monica, CA, New York, NY, and Jacksonville, FL – January 5, 2021 – Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”) announced today it has signed an agreement for a strategic investment in Web.com Group, Inc. (“Web.com” or the “Company”). Affiliates of Siris Capital Group, LLC (“Siris”), which acquired the Company in 2018, will remain significant equityholders in the platform together with Clearlake. Financial terms of the transaction were not disclosed.

Headquartered in Jacksonville, Florida, Web.com is a leading platform that enables businesses to establish, maintain, promote, and optimize their online presence. Web.com offers domain registration, hosting, website, and marketing services for businesses globally.  For more than 20 years, the Company has provided more than three million customers with competitive online solutions to support their changing business needs and drive results.

“Web.com provides market-leading web presence services in an attractive market segment that is seeing strong growth driven by accelerating digital transformation of small-and-medium sized businesses,” said James Pade, Partner, of Clearlake. “We look forward to partnering with Siris and leveraging Clearlake’s O.P.S.® playbook to accelerate growth.”

“This investment recognizes the strong execution of the Web.com team in providing best-in-class web presence solutions and delivering profitable growth,” said Tyler Sipprelle, Managing Director, of Siris.  “Web.com has bright prospects as a global, multi-brand web technology company, and we welcome Clearlake’s support of the business’s future growth.”

 

About Web.com

Web.com Group is a leading web technology company serving millions of customers around the world. Through our portfolio of brands – Network Solutions, Register.com, Web.com, CrazyDomains – we help customers of all sizes build an online presence that delivers results. Web has the breadth of capabilities and depth of knowledge to be your go-to partner in today’s always-on digital world. With our extensive product offerings and personalized support, we take pride in partnering with our customers to serve their online presence needs. Learn more at www.web.com.

 About Clearlake

Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with world-class management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are technology, industrials and consumer. Clearlake currently has approximately $25 billion of assets under management and its senior investment principals have led or co-led over 200 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.

 About Siris

Siris is a leading private equity firm that invests primarily in mature technology and telecommunications companies with mission-critical products and services, facing industry changes or other significant transitions. Siris’ development of proprietary research to identify opportunities and its extensive collaboration with its Executive Partners are integral to its approach. Siris’ Executive Partners are experienced senior operating executives that actively participate in key aspects of the transaction lifecycle to help identify opportunities and drive strategic and operational value. Siris is based in New York and Silicon Valley and has raised nearly $6 billion in cumulative capital commitments. www.siris.com.

 

Media Contacts

For Web.com:
Alex Sheehan
Finn Partners
+1 415-348-2734
webdotcom@finnpartners.com

For Clearlake:
Jennifer Hurson
Lambert & Co.
+1 845-507-0571
jhurson@lambert.com

For Siris:
Dana Gorman
Abernathy MacGregor
+1 212-371-5999
dtg@abmac.com

Blair Hennessy
Abernathy MacGregor
+1 212-371-5999
bth@abmac.com

Categories: News

Tags:

Andera Partners sells its Life Sciences’ portfolio company Arvelle Therapeutics

Andera Partners

Andera Partners sells its Life Sciences’ portfolio company Arvelle Therapeutics to Angelini Pharma in a deal valued at up to $960 million

Andera co-led the $207.5m Series A financing of Arvelle Therapeutics in February 2019 and joined the company’s board of directors. With the Series A funds, Arvelle in-licensed European product rights to Cenobamate from SK BioPharmaceuticals, prepared regulatory submission for the drug candidate and established a European structure.

Cenobamate is a small molecule with a unique dual complementary mechanism of action. It acts by positively modulating the γ-aminobutyric acid (GABAA) ion channel and inhibiting voltage-gated sodium currents. Key study findings documented Cenobamate’s clinical efficacy by showing a significant greater reduction in median seizure frequency and more patients achieving a 50% or greater reduction in seizure frequency compared to the placebo group (see press release link below). Cenobamate is approved by the Food and Drug Administration (FDA) in the United States as an anti-seizure medication for the treatment of focal-onset epileptic seizures in adults. In 2020 Arvelle filed for European approval of Cenobamate.

This transaction is the second industrial sale from Andera Life Sciences BioDiscovery 5 fund portfolio, following the sale of Corvidia to NovoNordisk for $2.1Bn in the summer of 2020. It further adds to four public listings of BioDiscovery 5 companies (Axonics, Erytech, LogicBio and Nyxoah), and occurs still during the funds’ investment period.

Share on :

Categories: News

Tags:

Genezen Laboratories Receives Growth Equity Investment from Ampersand Capital Partners

FISHERS, Ind., Jan. 5, 2021 /PRNewswire/ — Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production, and analytical testing services, today announced a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector. Ampersand’s investment will be used to complete the construction of the company’s 25,000 square foot cGMP-compliant lentiviral vector production facility, which will also offer a full suite of process development and analytical capabilities.

Genezen’s manufacturing facility, located north of Indianapolis in Fishers, IN, will leverage the company’s historical expertise in lentiviral vector production and development of cell and gene therapy products from preclinical through Phase I/II clinical development. The building will include multiple cGMP production suites, complete downstream processing and packaging capabilities, and comprehensive process development and analytical testing facilities. The process development laboratory will offer a range of customized production and analytical services, including those supporting cGMP and commercial readiness, upstream and downstream process improvements, research grade and preclinical vector production, and analytical assay development and validation. Analytical testing services, including Recombinant Competent Lentivirus testing (RCL), vector stability testing, and safety and sterility testing, will also be available. The company will round out its complete platform of cell and gene therapy CDMO services by continuing to offer cell manufacturing and patient sample testing through its existing academic partnerships.

Bill Vincent, Chairman and CEO of Genezen commented, “We are extremely pleased to be partnering with Ampersand in catalyzing the next phase of Genezen’s growth. Our recognized expertise in the lentiviral vector platform, combined with Ampersand’s unique cell and gene therapy CDMO experience, makes for a powerful combination. We look forward to providing a differentiated offering that will be critical in helping life-changing therapeutics reach the patients who need them.”

David Anderson, General Partner at Ampersand, added, “Given the ongoing growth of the cell and gene therapy sector, and the continued supply/demand imbalance in cGMP manufacturing, we are excited to partner with another specialized service provider in the space. We look forward to working with the Genezen team to leverage our deep experience with cell and gene therapy CDMOs to establish a leading platform in this revolutionary healthcare market.”



About Genezen Laboratories, Inc.

Founded in Indianapolis in 2014, Genezen Laboratories is focused on supporting the demands of the current and future gene and cell therapy manufacturing market worldwide— making viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen offers early-phase process development, GMP vector production, and analytical testing services, building on the company’s expansive knowledge and experience in the industry and working with the nation’s leading institutions. For more information, or to learn more about services offered in Genezen’s new cGMP facility, please visit genezenlabs.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at ampersandcapital.com.

Categories: News

Tags:

Chronosphere Releases First Monitoring Product Purpose-Built for Cloud-Native, Raises $43.4 Million in Funding

General Atlantic

Chronosphere, the company redefining monitoring for the cloud-native world, today announced the general availability of its award-winning monitoring product. This release comes after a year in beta during which Chronosphere onboarded customers from emerging startups like Tecton to later stage startups including one of the largest delivery app companies to well-known global brands including a multinational financial services company.

“We basically don’t think about monitoring anymore as we spin Tecton deployments up and down. It’s way better than it was before,” said Ravi Trivedi, software engineer at Tecton, an enterprise feature store company for machine learning.

Today’s monitoring tools are not equipped to handle the complex and dynamic nature of cloud-native environments and while the recommended open source tools like Prometheus help get companies started, they do not scale. Chronosphere delivers scalable, reliable and customizable monitoring purpose-built for companies adopting cloud-native.

Chronosphere’s product is powered by the open source metrics engine M3 that Chronosphere founders Martin Mao, CEO, and Rob Skillington, CTO, developed while at Uber. There they experienced first-hand the complexity and scale required to monitor cloud-native workloads. They solved this by scaling M3 to one of the largest production monitoring systems in the world storing tens of billions of time series and analyzing billions of data points per second in real-time.

“Everyone understands the business benefits of cloud-native architecture, but not many think about the implications,” said Mao. “For monitoring, you need a solution that is not only compatible with the rest of the ecosystem, but one that can also handle all of the data produced by the ephemeral and complex nature of these new environments.”

Chronosphere not only allows customers to store and retrieve the massive amounts of monitoring data produced by cloud-native environments, but it also does so with an order of magnitude more cost efficient than existing solutions. Additionally, Chronosphere lets customers understand and control their spending, even as the data continues to grow. This level of visibility and control is the first of its kind in an industry notorious for unexpected and uncontrollable bills. Chronosphere customers are estimated to reduce monitoring costs by up to 10 times.

Chronosphere’s monitoring product is provided as a hosted service, eliminating the need to manage monitoring infrastructure while maintaining 100% compatibility with cloud-native standards like Prometheus, PromQL and Grafana Dashboards. Customers can retain the vendor-neutral industry standards and tooling they have grown to love without worrying about the management overhead.

Chronosphere Raises a $43.4 Million Series B Growth Funding Round

Today Chronosphere also announced $43.4 million in Series B funding, bringing the total raised to $55 million. This round was led by previous investors Greylock, Lux Capital and venture capitalist Lee Fixel with participation from new investor General Atlantic.

Jerry Chen, Partner at Greylock and Chronosphere Board Member, said: “Chronosphere’s incredible customer wins and growth since Greylock led the Series A in 2019 show how badly customers need a cloud-native monitoring solution. In 2020, co-founders Martin and Rob have been able to hire strong team members, release critical product features, and close important customers. I look forward to continuing to partner with them as more customers experience the magic of Chronosphere’s monitoring product.”

Brandon Reeves, Partner at Lux Capital and Chronosphere Board Observer, said: “In just over a year since the Series A, customers ranging from decacorn startups to more than $100 billion in enterprise value publicly traded companies have chosen Chronosphere to monitor their mission critical workloads. And they have accomplished this with nearly a 100% pilot to production conversion.”

Anton Levy, Co-President, Managing Director, and Global Head of Technology Investing at General Atlantic, said: “Chronosphere is at the forefront of the shift to next-generation data monitoring, and offers the cost-effective scalability and reliability that leading enterprises need. We believe the company’s end-to-end solution – and application across a range of verticals – has the potential to transform the industry.”

Since formally launching in November 2019, Chronosphere has been named a Gartner Cool Vendor in Performance Analysis [1],  a Vendor to Watch by EMA, one of the 50 most promising startups by The Information, one of 31 commercial open source software startups that will thrive during Covid in Business Insider and a Startup to Watch by Built In NYC.

About Chronosphere

Chronosphere’s mission is to enable organizations to operate reliably at scale and make precise, data-driven decisions. Chronosphere provides solutions for scale, performance, reliability and cost efficiency. Chronosphere is backed by Greylock, Lux Capital, General Atlantic and Lee Fixel. For more information, visit https://chronosphere.io or follow @chronosphereio.

[1] Gartner, Cool Vendors in Performance Analysis, by Padraig Byrne and Gregg Siegfried, 5 October 2020 (report available to Gartner subscribers here).

Media Contacts

Mary Armstrong & Emily Japlon
General Atlantic media@generalatlantic.com

Categories: News

Tags:

Harrison Lung Joins Siris as Partner, Portfolio Value Creation

Siris

New York, January 4, 2021 – Siris, a leading private equity firm focused on investing and driving value creation in technology and telecommunications companies, today announced that Harrison Lung has joined the firm as Partner, Portfolio Value Creation. He most recently served as Partner at McKinsey & Company. Mr. Lung will lead Siris’ Operational Excellence group and work alongside Siris’ teams and Executive Partners to deliver on the value creation potential of Siris portfolio companies across the entire deal lifecycle.

 

For the past decade, Mr. Lung has implemented pivotal strategies across McKinsey’s digital technology and technology-media-telecom (TMT) clients, helping drive transformations and efficiency in digital and technology infrastructure, operations and organizational structures and processes. His combination of deep technology experience and history of improving global businesses will help Siris as it seeks to accelerate growth across its portfolio companies, while reducing costs and enhancing operational efficiency and sophistication.

 

Frank Baker, Co-Founder of Siris, said, “We are excited to welcome Harrison to lead our Operational Excellence group and look forward to benefiting from his experience at McKinsey transforming dynamic technology businesses. We are confident in his ability to help design and implement sophisticated, efficient solutions for our portfolio companies.”

 

Mr. Lung said, “I am thrilled to join Siris as the firm continues to drive growth across technology and telecommunications businesses that deliver mission-critical products and services. I look forward to working with my new colleagues in Siris’ Operational Excellence group to optimize the application of best practices across the portfolio.”

 

Prior to joining McKinsey & Company in 2010, Mr. Lung worked in Accenture’s System Integration, Technical Architecture (Mobile Solutions) and New Business groups, where he served as part of the leadership team that built and scaled an internally incubated startup – Accenture Mobility Operated Service – and facilitated transformative growth for Fortune 500 companies in the pharmaceutical, utility, telecom, chemical and energy sectors.

 

Earlier in his career, Mr. Lung served in technology operating roles in the telecom industry in Canada, at Bell Mobility and Sprint Canada, and was part of the leadership team that implemented Wireless Number Portability. Mr. Lung has been a member of Asia Society’s Global Talent and Diversity Council since 2019 and an ambassador at the Cornell Alumni Admissions Ambassador Network (CAAAN) since 2020.

 

Mr. Lung holds a Bachelor of Applied Science in Computer Engineering from the University of Waterloo and an Executive MBA from Cornell University and Queen’s University.

 

About Siris

 

Siris is a leading private equity firm that invests primarily in mature technology and telecommunications companies with mission-critical products and services, facing industry changes or other significant transitions. Siris’ development of proprietary research to identify opportunities and its extensive collaboration with its Executive Partners are integral to its approach. Siris’ Executive Partners are experienced senior operating executives that actively participate in key aspects of the transaction lifecycle to help identify opportunities and drive strategic and operational value. Siris is based in New York and Silicon Valley and has raised nearly $6 billion in cumulative capital commitments. www.siris.com.

 

Media Contacts

 

Dana Gorman or Blair Hennessy
Abernathy MacGregor
1-212-371-5999
dtg@abmac.com / bth@abmac.com

Categories: People

Gladstone Investment Corporation Exits its Investment in Frontier Packaging

Gladstone

MCLEAN, VA / ACCESSWIRE / January 4, 2021 / Gladstone Investment Corporation (NASDAQ:GAIN) (“Gladstone Investment”) announced today the sale of its portfolio company Frontier Packaging, Inc. (“Frontier Packaging,” or “Frontier”). As a result of this transaction, Gladstone Investment received repayment of its debt investment at par and realized a significant gain on its equity investment. Gladstone Investment acquired Frontier Packaging in partnership with management in 2012.

Frontier Packaging, headquartered in Tukwila, WA, is a market-leading provider of packaging materials to the fish processing industry across the Pacific Northwest and Alaska.

“Gladstone Investment has developed a strong relationship with Frontier’s management team over nearly a decade. We believe this is the strongest management team in the industry and are proud to have supported them through a period of sustained growth,” said Kyle Largent, Executive Vice President of Gladstone Investment. “We wish Frontier and the management team continued success.”

“With our sale of Frontier Packaging and from our inception in 2005, Gladstone Investment has exited over 20 of its management supported buy-outs, generating significant net realized gains on these investments in the aggregate,” said David Dullum, President of Gladstone Investment. “Our strategy as a buyout fund, realizing gains on equity, while also generating strong current income during the investment period from debt investments alongside our equity investments, provides meaningful value to our shareholders through stock appreciation and dividend growth. Significant winners like Frontier prove out our focus on buying high quality businesses, backing outstanding management teams and being able to have investments with long hold periods.”

Gladstone Investment Corporation is a publicly traded business development company that seeks to make secured debt and equity investments in lower middle market private businesses in the United States in connection with acquisitions, changes in control and recapitalizations. Additional information can be found at www.gladstoneinvestment.com.

For Investor Relations inquiries related to any of the monthly distribution-paying Gladstone family of funds, please visit www.gladstonecompanies.com.

Forward-looking Statements:

The statements in this press release regarding the longer-term prospects of Gladstone Investment and Frontier Packaging and its management team, and the ability of Gladstone Investment and Frontier Packaging to be successful in the future are “forward-looking statements.” These forward-looking statements inherently involve certain risks and uncertainties in predicting future results and conditions. Although these statements are based on Gladstone Investment’s current beliefs that are believed to be reasonable as of the date of this press release, a number of factors could cause actual results and conditions to differ materially from these forward-looking statements, including those factors described from time to time in Gladstone Investment’s filings with the Securities and Exchange Commission. Gladstone Investment undertakes no obligation to update or revise these forward looking statements whether as a result of new information, future events or otherwise, except as required by law.

For further information: Gladstone Investment Corporation, 703-287-5810

SOURCE: Gladstone Investment Corporation

View source version on accesswire.com:
https://www.accesswire.com/622824/Gladstone-Investment-Corporation-Exits-its-Investment-in-Frontier-Packaging

Categories: News

Tags: